Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021
Open Access
How can we achieve LDL-C goals in ASCVD?
29 August 2021
Open Access
Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)